Core Viewpoint - The stock price of Peijia Medical-B (02565.HK) fell by 5.54% to HKD 63.05 on February 13, primarily due to a combination of market weakness, profit-taking after index inclusion, technical pressure, funding discrepancies, and high valuation concerns [1][5]. Stock Performance - On February 13, the Hang Seng Index dropped by 1.72%, and the biotechnology sector declined by 0.95%, indicating increased risk aversion in the market, leading to capital outflows from growth sectors like pharmaceuticals [2]. Reasons for Stock Price Movement - Peijia Medical-B was announced to be included in the Hang Seng Composite Index effective March 9, 2026. However, this positive news was partially anticipated by the market, as the stock had already risen approximately 4.7% over February 11 and 12. On February 13, the stock opened high but fell after reaching a peak of HKD 67.40, suggesting profit-taking by some investors [3]. Funding and Technical Analysis - The closing price of HKD 63.05 on February 13 was below both the 5-day moving average (HKD 65.27) and the 20-day moving average (HKD 65.515). The MACD histogram, while positive, remained below the zero line, indicating a bearish short-term trend. The stock experienced a volatility of 9.51%, with a low of HKD 61.05, near the lower Bollinger Band (HKD 58.974), reflecting strong selling pressure. Although there was a net inflow of HKD 335.67 million, it was primarily driven by retail investors, with institutional investors showing a cautious stance [4]. Company Valuation - As of February 13, the company's trailing twelve months (TTM) price-to-earnings ratio was -101.56, and the price-to-book ratio was 42.84, indicating a high valuation level. The company’s R&D expenditure for the mid-2025 period was HKD 26.294 million, suggesting significant ongoing investment pressure. Market concerns may arise regarding the alignment of its earnings outlook with current valuation levels [5].
派格生物医药-B股价下跌5.54%，受板块走弱及利好兑现影响